This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.
Male or female patients aged ≥19 years at the time of enrollment.
Patients with moderate to severe psoriasis persisting for ≥6 months.
Patients with a PASI (Psoriasis Area and Severity Index) score between 5 and 10, requiring pharmacological treatment.
Patients who have been fully informed about the study, have understood the explanation, and have voluntarily signed the informed consent form.
Patients with a history of hypersensitivity to apremilast.
Patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Pregnant or breastfeeding women.
Patients (or their spouse/partner) who do not agree to use medically acceptable and appropriate methods of contraception* during the study period.